Interestingly, patients with CLL had significantly increased levels of CD19+CD27−IgD+ naïve B cells 5.190% (6.78–4.40) when compared to the control group 0.97% (1.35–0.69), p < 0.0001 (Fig. 2D). Here, CD19 is linked to B-cell chronic lymphocytic leukemia.